Preparing for the 2010-2011 Influenza Season
by Sheila M. litchfield, rN, BSN, COHN-S, COHC I nfluenza morbidity caused by 2009 pandemic influenza A (H1N1) remained above seasonal baselines throughout spring and summer 2009 and was the cause of the first pandemic since 1968. In the United States, the pandemic was characterized by a substantial increase in influenza activity, as measured by multiple influenza surveillance systems, that was well beyond historical norms beginning in September 2009, peaking in late October 2009, and returning to seasonal baseline by January 2010. During this time, more than 99% of viruses were the 2009 pandemic influenza A (H1N1) virus (Centers for Disease Control and Prevention [CDC], 2010c) .
Due to the 2009 influenza A (H1N1) pandemic experience, the CDC and state health departments are encouraging a few key best practices to ensure broad dissemination of influenza vaccine in anticipation of the upcoming influenza season. The recommendations include:
l Holding flu vaccination clinics early in the fall. l Conducting small clinics in a variety of settings, including schools, meeting places, and work sites. l Encouraging collaborations between health care providers and schools to use available resources.
Last year, nurses across the country came together in support of vaccination clinics in schools and other settings. Some flu clinics were targeted to specific populations, while others were open to the public. This use of resources established new informal networks of health care providers that greatly enhanced the capability of local Emergency Dispensing Sites (EDS) to provide government-issued vaccine to the general public. In some communities, dissemination of influenza vaccine in this manner was a test of local EDS capabilities and provided an opportunity to identify previous-ly unknown volunteer health care providers.
CDC ReCommenDS Influenza VaCCInatIonS foR InDIVIDualS 6 monthS anD olDeR
This year, in preparation for the 2010-2011 influenza season, the Advisory Committee on Immunization Practices (ACIP) has established a universal vaccination recommendation for all individuals 6 months and older. The expansion of the recommendation for annual vaccination is supported by the CDC estimation that 85% of the U.S. population already had an indication for influenza vaccination and believed influenza vaccines are safe and effective. Additionally, due to the increased demand for vaccine production last year, the capacity to produce sufficient quantities of vaccine to meet demand has been enhanced (Fiore et al., 2010) . As a result of the ACIP recommendation, the CDC is encouraging individuals 6 months and older to receive the flu vaccine as soon as vaccine is available this fall. This recommendation significantly expands the need to disseminate information about influenza vaccination and stresses the need for more vaccination clinics in a variety of settings. Proactive collaborations among schools, work sites, hospitals, private practices, college health centers, and other local health resources will be vital in broader dissemination of influenza vaccine.
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HealtH nursing currents
Although flu is unpredictable, it is likely that 2009 H1N1 viruses and regular seasonal viruses will cause illness in the United States this flu season. The 2010-2011 flu vaccine will protect against three flu viruses: an H3N2 virus, an influenza B virus, and the H1N1 virus that caused much of the illness last season. Individuals are encouraged to be vaccinated this year even if they were vaccinated last year because the vaccine viruses have been updated. Immunity occurs about 2 weeks after vaccination, and the flu vaccine provides protection throughout the entire flu season (CDC, 2010b).
leSSonS fRom the 2009 Influenza a (h1n1) PanDemIC exPeRIenCe
The ACIP recommendation to expand vaccination to include all adults is based on data from the 2009 influenza A (H1N1) pandemic experience indicating that the risk for influenza complications among adults younger than 50 years who had 2009 pandemic influenza A (H1N1) is greater than is typically seen for seasonal influenza. Explosive outbreaks of 2009 H1N1 influenza among young adults in settings such as college campuses were part of the reason for prioritizing vaccination of all individuals 6 months to 24 years old during the 2009 pandemic influenza response. Pandemic 2009 influenza A (H1N1)-like viruses are expected to continue to circulate during the 2010-2011 influenza season, and a substantial proportion of young adults do not yet have immunity as a result of natural infection with this virus (Fiore et al., 2009) . In addition, severe infections were observed more frequently in some younger adults who did not have previously recognized risk factors for influenza-related complications, including obese individuals, individuals of specific racial and ethnic minority groups, and postpartum women. As a result, the recommendations for target populations for vaccination when supplies are limited have been expanded to include two new groups: American Indians/Alaska Natives and individuals who are morbidly obese (body mass index > 40) (Fiore et al., 2010) . Other minority groups, including Blacks, have been shown to have a higher incidence of hospitalizations as a result of laboratory-confirmed influenza compared to Whites (CDC, unpublished data, 2010) . Additional study is needed to determine the reasons for this. Individuals with chronic health-related conditions, who are pregnant, or who are at higher risk for 2009 H1N1 influenza-related complications should be encouraged to receive annual influenza vaccination.
Influenza VaCCIne foRmulaRy
Trivalent influenza vaccine (TIV) contains three inactivated viruses and thus cannot cause influenza. Live attenuated influenza vaccine (LAIV) contains live attenuated influenza viruses that have the potential to cause mild signs or symptoms related to vaccine virus infection (e.g., rhinorrhea, nasal congestion, fever, or sore throat). The LAIV formulary is a weakened form of influenza virus that is cold-adapted and temperature sensitive. It is able to replicate only at the temperatures present in the nasal mucosa. LAIV is administered intranasally by sprayer, whereas TIV is administered intramuscularly by injection. LAIV is licensed for use among nonpregnant individuals 2 to 49 years old. Safety has not been established for individuals with underlying health-related conditions that confer a higher risk for influenza complications. TIV is licensed for use among individuals who are 6 months or older, including those who are healthy and those with chronic health-related conditions. During the preparation of TIV, the vaccine viruses are made noninfectious (i.e., inactivated or killed) (Fiore et al., 2010) . A newly licensed higher dose TIV (60 mcg per each 3 vaccine strains or 180 mcg total hemagglutinin antigen) was approved recently for individuals 65 years and older (Fluzone High-Dose, Sanofi Pasteur, Swiftwater, PA) (Fiore et al., 2010) .
VaCCIne PReSeRVatIVe (thImeRoSal) In multIDoSe VIalS of tIV
Thimerosal, a mercury-containing antibacterial compound, has been used as a preservative in vaccines and other medications since the 1930s. It is used in multidose vial preparations of TIV to reduce the likelihood of bacterial growth. Although no scientific evidence indicates that thimerosal in vaccines is a cause of adverse events other than occasional local hypersensitivity reactions in recipients, the U.S. Public Health Service and other organizations have recommended that thimerosal be eliminated or reduced in vaccines as part of a strategy to reduce mercury exposures from all sources (CDC, 2000) . Also, continuing public concern about exposure to mercury in vaccines has been viewed as a potential barrier to achieving higher vaccine coverage levels. Since mid-2001, vaccines routinely recommended for infants 6 months and younger in the United States have been manufactured either without or with greatly reduced (trace) amounts of thimerosal. The ACIP and other federal agencies and professional health care organizations continue to support efforts to provide thimerosal-free vaccine options. LAIV formulary does not contain thimerosal.
SheDDIng of laIV VIRuSeS
Available data indicate that both children and adults vaccinated with LAIV can shed vaccine viruses after vaccination, although in lower amounts than occur typically with shedding of wild-type influenza viruses. Although rare, shed vaccine viruses can be transmitted from vaccine recipients to unvaccinated individuals. However, serious illnesses have not been reported among unvaccinated individuals who have been infected inadvertently with vaccine viruses (Fiore et al., 2010) . No instances of illness or attenuated vaccine virus infections have been reported among inadvertently exposed health care personnel or immunocompromised patients. The risk for acquiring vaccine viruses from the environment, although unknown, is probably low. In addition, LAIV occupational HealtH nursing currents vaccine viruses are cold-adapted and attenuated, and unlikely to cause symptomatic influenza. Severely immunosuppressed individuals should not administer LAIV. However, other individuals at higher risk for influenza complications (e.g., individuals with underlying health-related conditions placing them at higher risk or who are likely to be at risk, including pregnant women, individuals with asthma, and individuals 50 years and older) can administer LAIV.
new hIgh-DoSe VaCCIne foR InDIVIDualS 65 yeaRS anD olDeR
Individuals 65 years and older are at greater risk of serious complications from the flu compared with young, healthy adults. Each year in the United States, an estimated 90% of seasonal flu-related deaths and more than 60% of seasonal flu-related hospitalizations occur among individuals 65 years and older. This is because of human immune defenses weakening with age. Thus, influenza can be serious among individuals 65 years and older.
This season, two flu vaccinations will be available for individuals 65 years and older: a regular dose flu vaccine and a new flu vaccine designed for individuals 65 and older with a higher dose. The high-dose vaccine is associated with a stronger immune response to vaccination; whether this results in greater protection against influenza illness in older adults is not yet known. The CDC and ACIP have not expressed a preference for either vaccine (CDC, 2010a) .
Additional information about Fluzone High-Dose can be found on the Food and Drug Administration website (www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm112854.htm). Before administering Fluzone High-Dose vaccine or Fluzone vaccine, the full prescribing information should be reviewed (www. vaccineplace.com/products).
RatIonale foR woRkPlaCe Influenza VaCCIne ClInICS
Despite the recommendation during the past two seasons that ap-proximately 85% of the U.S. population receive vaccination, less than 50% of the U.S. population received a seasonal influenza vaccination in 2008-2009 or 2009-2010 . Estimated vaccine coverage for the 2009 H1N1 monovalent vaccine was less than 40% (Fiore et al., 2010) .
Expansion of the recommendation to all individuals 6 months and older highlights the importance of making influenza vaccine readily accessible in a variety of settings. Many of the individuals at highest risk for complications will likely continue to be vaccinated in health care settings. However, vaccination in health care settings must increasingly be complemented by vaccination in non-health care settings that increase convenience and access. During the 2009-2010 H1N1 vaccination program, substantial effort was made at the state and local levels to direct vaccine to locations such as schools, pharmacies, workplaces, and health departments.
Workplace vaccination programs provide an efficient means of improving public health and potentially reducing absenteeism due to influenza-like illness. In addition, working adults with young children are at greater risk of exposure, as children typically have the highest attack rates during community outbreaks of influenza and serve as a major source of transmission within communities. Although vaccinating children is most important, vaccinating individuals who have close contact with children can reduce overall transmission within communities. Achieving and maintaining community-level reductions in influenza will require mobilization of a wide variety of resources and development of sustainable annual vaccination campaigns. In some workplaces, annual vaccine campaigns have included employees' family members and the general public, bolstering company public relations.
taRget PoPulatIonS when VaCCIne SuPPly IS lImIteD
Vaccination to prevent influenza is particularly important for individuals who are at increased risk for severe complications from influenza. When vaccine supply is limited, vaccination efforts should focus on the following individuals (Fiore et al., 2010) Household contacts and caregivers of children younger than 5 years and adults 50 years and older, with emphasis on vaccinating contacts of children younger than 6 months. l Household contacts and caregivers of individuals with health-related conditions placing them at higher risk for severe complications from influenza.
CoSt-effeCtIVeneSS of Influenza VaCCInatIon
Economic studies of influenza vaccination are difficult to compare because of varying measures of both costs and benefits (e.g., cost-only, cost-effectiveness, cost-benefit, or cost-utility measures). However, most studies indicate that vaccination reduces or minimizes health care, societal, and individual costs and the productivity losses and absenteeism associated with influenza illness. One national study estimated the annual economic burden of seasonal influenza in the United States (using occupational HealtH nursing currents occupational HealtH nursing currents 2003 population and dollars) to be $87.1 billion, including $10.4 billion in direct health care costs (Molinari et al., 2007) .
Economic analyses among adults younger than 65 years have reported mixed results regarding influenza vaccination. Two studies in the United States indicated that vaccination can reduce both direct health care costs and indirect costs from work absenteeism and reduced productivity (Nichol, 2001; Nichol, Mallon, & Mendelman, 2003) . However, another U.S. study indicated no productivity and absentee savings in a strategy to vaccinate healthy working adults, although vaccination still was estimated to be costeffective (Meltzer, Neuzil, Griffin, & Fukuda, 2005) . In Ontario, Canada, where a universal influenza vaccination program was implemented beginning in 2000, costs were estimated to be approximately twice as much as a targeted vaccination program. However, the number of cases of influenza was reduced 61%, and influenza-related mortality declined 28%. In this study, most of the cost savings was attributed to avoiding hospitalization (Sander et al., 2010) .
SummaRy
The CDC recommends that health care providers begin offering influenza vaccine as soon as the vaccine becomes available and continue vaccination efforts throughout the season to prevent missed opportunities to protect individuals from influenza. Influenza disease activity typically peaks in the winter during February and March. Individuals who have not received their immunization early in the season will have time to do so prior to the peak of influenza season. As long as influenza viruses are in circulation, influenza vaccination is of value even in December and January and into the spring.
Vaccination clinics should be held in a variety of settings. Health care personnel are encouraged to collaborate to vaccinate a majority of the population. Influenza vaccination can be provided to employees in the workplace. Workplace vaccination campaigns can meet both employee and employer needs.
